Research programme: neurological disorder therapeutics - Delix Therapeutics
Latest Information Update: 11 Jun 2024
At a glance
- Originator Delix Therapeutics
- Class Neuropsychotherapeutics; Sensory system agents; Small molecules
- Mechanism of Action Nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hearing loss; Neurological disorders; Psychotic disorders